Tag: Coronavirus
-
Revive Therapeutics (RVV.C) to have 10 clinical COVID-19 FDA trial sites by end of year
Earlier this year, when Revive Therapeutics (RVV.C) announced they had some pharma IP that may be relevant to the treatment of COVID-19, plenty of folks laughed uproariously at the thought that a three time loser might be relevant in 2020. Having missed on an earlier pharma focus, and come to the cannabis party a little…
-
![Xphyto (XPHY.C) advances its Oral Dissolvable Film (ODF) technology for CBD and THC medical markets]()
Xphyto (XPHY.C) advances its Oral Dissolvable Film (ODF) technology for CBD and THC medical markets
Increased product efficacy and patient convenience is anticipated through faster onset of drug action, more predictable therapeutic activity and ease of use.
-
![Xphyto (XPHY.C) updates shareholders on rapid COVID-19 (SARS-CoV-2) screening test]()
Xphyto (XPHY.C) updates shareholders on rapid COVID-19 (SARS-CoV-2) screening test
Xphyto and 3a are developing rapid screening tests for COVID-19 and other high-risk pandemic threats, including H1N1 (swine flu) and H5N1 (avian flu), with a specific focus on early pre-symptomatic and asymptomatic stages of infection
-
![That was quick: Valeo Pharma (VPH.C) gets Health Canada nod for immune system booster]()
That was quick: Valeo Pharma (VPH.C) gets Health Canada nod for immune system booster
“There is a strong scientific and medical rationale for the use of Hesperco capsules to support the immune system,” stated Pierre Laurin, CEO of Ingenew, who added that it could “potentially fight off symptoms associated with coronaviruses.”
-
![Xphyto’s (XPHY.C) COVID-screener: this bio-tech company ain’t spit-balling]()
Xphyto’s (XPHY.C) COVID-screener: this bio-tech company ain’t spit-balling
Xphyto’s test may be ideal to catch the super-spreaders – the infectious carriers blithely attending drumming circles because they feel healthy.
-
Valeo Pharma Inc. (VPH.C) – THE undervalued biotech play
If you’re one of the discerning readers who bought Valeo Pharma’s stock since the last article I posted on July 6th, 2020: congratulations you should be making over 38% returns on your investment. Better yet, if you had bought Valeo’s stock a month ago, you would have been up close to 184%, which, y’know, is…
-
XPhyto (XPHY.C) advances a COVID-screener that works like a pregnancy test
“Visual confirmation of test results (probe activation) was observed in five to seven minutes,” states Xphyto.
-
Roadman Investments (LITT.V) really doesn’t want to talk about cedar leaf oil anymore
One of Roadman Investments (LITT.V) subsidiaries, CLOV Biopharma, recently completed its research program at UBC on cedar leaf oil vapour, but the Securities Exchange Commission (SEC) doesn’t care. The research program has taken a bit longer than the company would have liked, courtesy of COVID-19, but the company’s doctors have acquired most of the exemptions…
-
Xphyto (XPHY.C) just unlocked a pipeline of biosensor screening projects
Our early coverage of Xphyto reveals the following company trait: Xphyto says, “We’re going to do this” – and then they do it – quickly.
-
![Xphyto (XPHY.C) advances delivery system for Parkinson’s drug]()
Xphyto (XPHY.C) advances delivery system for Parkinson’s drug
Vektor is now proceeding with process implementation for the manufacture of Rotigotine patches for human clinical studies.
